If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
GHRH 1-29 fragment
Research documentation
Sermorelin is supplied for laboratory research. Contact sales to confirm the available identity, purity, and lot records, and discuss the evidence your assay or method-development project requires.
Overview
As a growth-hormone-releasing hormone (GHRH) receptor agonist, Sermorelin corresponds to residues 1-29 at the N-terminus of endogenous human GHRH and preserves the complete receptor-activating capacity carried by the full 44-residue hormone. Because it is the best-characterized GHRH-receptor ligand, it functions as the benchmark to which later engineered variants such as Modified GRF 1-29, Tesamorelin, and the CJC-1295 constructs are referenced. A short circulating window of about 10-12 minutes, driven by DPP-4 scission at the Tyr1-Ala2 position, defines its pharmacokinetics; this very liability is what prompted the stabilizing substitutions that gave rise to the CJC-1295 lineage. Historically it reached the clinic as Geref, indicated for diagnostic assessment of pediatric GH deficiency. Lyochem supplies Sermorelin acetate as a lyophilized reference standard to a ≥99.0% HPLC purity specification. At 29 residues the target is comfortably within dependable solid-phase assembly, and every released lot comes with its batch COA covering RP-HPLC purity by peak integration and ESI-MS identity confirmation; Karl Fischer water determination and acetate counter-ion quantitation are available on request and listed on the COA when tested. In practice the material supports GHRH-receptor pharmacology studied on physiologic timescales, where the rapid clearance is deliberately exploited for pulse-signaling work; investigators needing a sustained-exposure profile instead turn to CJC-1295 with DAC.
Applications & buyer fit
GH-axis peptides ship to research labs studying somatotropic-pathway pharmacology and related models. Ask sales for the matching batch COA. Sequence, counter-ion, or stability evidence beyond that record is included only when required by a written project scope and agreed before quotation.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Biotech R&D Groups
Preclinical biotech and pharmaceutical discovery teams sourcing characterized peptides for receptor-pharmacology, screening, and method-development campaigns.
Every lot has its own batch-specific CoA — HPLC purity and MS identity, plus any analytical scope agreed at quote stage — tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration — Lyochem's GH-axis lots are scoped to research workflows only. Buyers studying somatotropic pharmacology should specify the counter-ion form (acetate by default) and any pulse-vs-sustained study design notes at quote stage.
Selected literature
Frequently asked questions
Sermorelin is a defined 29-residue sequence, so certification rests on chromatography plus mass, backed by fragmentation where needed. RP-HPLC establishes purity and separates deletion and truncation species that accumulate during synthesis of a chain this length. ESI-MS confirms the intact mass, deconvoluted from a multiply-charged envelope, against the theoretical value for the 1-29 fragment. Because several analogs in this family are built on the same GHRH backbone, LC-MS/MS residue-ladder confirmation is available to prove the unmodified sequence rather than a substituted variant. We transcribe the measured purity, mass, and chromatogram onto the certificate for the specific lot.
The pharmacokinetic modifications that separate these molecules are also their identity markers. CJC-1295 carries amino-acid substitutions and Tesamorelin an N-terminal acyl group, so each reads at a different intact mass from the unmodified 1-29 fragment by ESI-MS, and the modifications shift RP-HPLC retention under a fixed gradient. Running the received lot beside a Sermorelin reference confirms it co-elutes with the native fragment rather than a protease-resistant analog. Where masses run close, LC-MS/MS distinguishes them by locating the substitution or the acyl modification in the sequence. We anchor each lot to its measured mass and retention on the certificate.
Related peptides
Modified GRF 1-29 · GHRH analog
Ghrelin / GHSR pathway GH-release peptide
57-mer
GHRH analog · approved for HIV-associated lipodystrophy